Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 10/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 3/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177919 | 0.98 | ATR (0.41) | ATRMTORF2PIK3CA | |
| SCHEMBL10177694 | 0.87 | ATR (0.44) | ATR | |
| SCHEMBL10177770 | 0.87 | ATR (0.52) | ATRMTOR | |
| SCHEMBL10177700 | 0.86 | ATR (0.39) | ATRCHEK1PARP1PARP2 | |
| SCHEMBL10230616 | 0.86 | ATR (0.49) | ATR | |
| SCHEMBL10177728 | 0.85 | ATR (0.41) | ATR | |
| SCHEMBL10177887 | 0.84 | ATR (0.37) | ATR | |
| SCHEMBL10231342 | 0.84 | ATR (0.48) | ATR | |
| SCHEMBL10177745 | 0.83 | ATR (0.41) | ATRPARP1PARP2 | |
| SCHEMBL10177738 | 0.83 | ATR (0.37) | ATRRIPK2MTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, CHEK2 | ATR 1/4885DGAT1 4235/4885RIPK2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.